Puma Biotechnology (NASDAQ:PBYI) Stock Quotes and News

63.25 1.35 (2.18%)

After Hours 63.3 (%)

Data as of Apr 25, 2018

Prev. Close 61.9
Price Open 61.9
Volume 330,246
Day's Range 60.8554 - 63.65
52 Wk Range 28.35 - 136.9
50 Day Moving Avg. 68.46
PE Ratio 0
Shares Outstanding 36.97M
Market Cap 2.34B

Trade PBYI stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

Date	Research Firm	Action	Current	Target
4/12/18	Barclays	Downgrades	OverweightEqual-Weight	0.0
3/09/18	Stifel Nicolaus	Maintains	BuyBuy	95.0
3/02/18	Barclays	Maintains	OverweightOverweight	90.0

Barclays Downgrades Puma Biotechnology to Equal-Weight Eddie StaleyThu, 12 Apr 2018 06:39:19 -0400
Puma Biotech, Pint Pharma Report Exclusive Licensing Deal To Commercialize Neratinib In Latin America Paul QuintaroTue, 03 Apr 2018 08:45:39 -0400
Puma Biotechnology Announces that NERLYNX Has Been Included as a Treatment Option in the National Comprehensive Cancer Network Paul QuintaroMon, 02 Apr 2018 08:49:16 -0400
Barclays Maintains Overweight on Puma Biotechnology, Lowers Price Target to $90.00 Vick MeyerFri, 02 Mar 2018 13:17:27 -0400
Puma Biotechnology Reports Q4 Adj. EPS $(1.03) vs $(1.98) Est., Sales $20.1M vs $20.0M Est. Paul QuintaroThu, 01 Mar 2018 17:12:48 -0400
Puma Biotech Shares Quiet Premarket Following EMA Recommendation Against Approval Of Co.'s Neratin Paul QuintaroFri, 23 Feb 2018 08:22:10 -0400
Leerink Partners Global Healthcare Conference Begins Today, Presenters Include: Dova Pharma, Heron Therapeutics, Sage Therapeutics, Enanta, The Medicines Company, Puma Biotech, Dicerna Pharma, Biogen, bluebird bio, and Alexion Pharma Hal LindonWed, 14 Feb 2018 08:06:46 -0400
Puma Biotechnology, CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX In China; Puma To Receive $30M Upfront And $40M In Potential Milestone Payments Eddie StaleyThu, 01 Feb 2018 17:22:29 -0400
Puma Biotech Reports Publication Of Results From Phase II SUMMIT Basket Trial On Neratinib In HER2, HER3 Mutant Cancers Paul QuintaroWed, 31 Jan 2018 14:17:06 -0400
Puma Biotech Shares Ticking Modestly Lower As Traders Circulating FDA.gov Alert 'FDA limits packaging for anti-diarrhea medicine Loperamide (Imodium) to encourage safe use' Paul QuintaroTue, 30 Jan 2018 11:58:22 -0400
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results Business Wire2 hours ago
Free Research Reports on These Biotech Stocks -- Prothena, PTC Therapeutics, Pulmatrix, and Puma Biotech PRNewswireApr 13, 2018
Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America Business WireApr 03, 2018
NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast Cancer Brain Metastases Business WireApr 02, 2018
Robbins Geller Rudman & Dowd LLP Announces Pending Class Action in the Puma Biotechnology, Inc. Litigation Business WireMar 28, 2018
Puma Biotechnology to Present at Cowen's Annual Healthcare Conference Business WireMar 06, 2018
Puma Biotechnology Reports Fourth Quarter and Full Year 2017 Financial Results Business WireMar 01, 2018
Puma Biotechnology, Inc. to Host Earnings Call PRLiveMar 01, 2018
Puma Biotechnology Receives Results of CHMP Formal Decision for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer Business WireFeb 23, 2018
New Research Coverage Highlights SunCoke Energy Partners, Carrols Restaurant Group, First Financial, Emerson Electric, Puma Biotechnology, and Amgen — Consolidated Revenues, Company Growth, and Expectations for 2018 Globe NewswireFeb 20, 2018
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

ASLAN Pharmaceuticals Updates U.S. IPO Plans Seeking AlphaApr 18, 2018
ASLAN Pharmaceuticals Files For $86 Million U.S. IPO Seeking AlphaApr 06, 2018
3 Things In Biotech, April 3: Alkermes Gets Into Trouble, Puma Gets Into Your Head, Myriad Gets Into Japan Seeking AlphaApr 04, 2018
Your Daily Pharma Scoop: MediciNova Makes A Strong Comeback, Alkermes' Setback, BioLife Preliminary Q1 Results Seeking AlphaApr 03, 2018
Puma Bio establishes Nerlynx commercialization in Latin America Seeking AlphaApr 03, 2018
Puma Bio's Nerlynx in treatment guidelines for certain breast cancer patients Seeking AlphaApr 02, 2018
Puma Biotechnology (PBYI) Up 10.2% Since Earnings Report: Can It Continue? ZacksApr 02, 2018
3 Things In Biotech, March 26: A Focus On European Opinions Seeking AlphaMar 27, 2018
Henderson Group Plc Buys Aptiv PLC, IQVIA Holdings Inc, The Home Depot Inc, Sells Delphi ... GuruFocusMar 12, 2018
Puma Biotechnology Inc (PBYI) Files –…-K for the Fiscal Year Ended on December '–, ... GuruFocusMar 09, 2018
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q4 2017	EST	Actual	Surprise
EPS:	-1.98	-1.03	0.95
Rev:	20.01M	20.10M	90.00K

Q1 2018	EST	Actual	Surprise
EPS:	-1	Expected 2018-05-09
Rev:	58.50M	Expected 2018-05-09

Brokerage Center

Compare All Online Brokerages

Market Overview

Puma Biotechnology PBYI:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners

Membership is Free

What are you waiting for? Sign up now!

Free Account Login

Market Overview

Tickers

Articles

Keywords

Puma Biotechnology PBYI:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners